SCHEMBL5450745

SCHEMBL5450745

NC(=O)c1c(NC(=O)C2CC2)sc2c1CCOC2NCCN1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.46
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 9/20 0.42
HPGD P15428 5/20 0.42
KDM4E B2RXH2 3/20 0.42
MAPT P10636 2/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TSHR P16473 3/20 0.40
HSD17B10 Q99714 3/20 0.40
REV1 Q9UBZ9 2/20 0.40
MAPK10 P53779 1/20 0.40
MDM2 Q00987 1/20 0.40
GAA P10253 1/20 0.39
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ALOX15 P16050 1/20 0.37
CNR2 P34972 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5454125 0.93 FLT3 (0.43) FLT3MEN1KMT2AALDH1A1HPGD
SCHEMBL5457867 0.87 KMT2A (0.46) FLT3MEN1KMT2AALDH1A1HPGD
SCHEMBL5455200 0.82 FLT3 (0.46) FLT3MEN1KMT2AALDH1A1HPGD
SCHEMBL5457860 0.80 FLT3 (0.44) FLT3MEN1KMT2AALDH1A1HPGD
SCHEMBL5459168 0.76 FLT3 (0.40) FLT3KMT2AALDH1A1HPGDKDM4E
SCHEMBL5458319 0.76 FLT3 (0.46) FLT3MEN1KMT2AALDH1A1HPGD
SCHEMBL5451643 0.74 FLT3 (0.55) FLT3MEN1KMT2AALDH1A1HPGD
SCHEMBL5451709 0.74 FLT3 (0.41) FLT3MEN1KMT2AALDH1A1HPGD
SCHEMBL5449035 0.74 FLT3 (0.47) FLT3MEN1KMT2AALDH1A1HPGD
SCHEMBL5460990 0.73 BTK (0.41) FLT3MEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885MEN1 2891/4885KMT2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.